The efficacy of IL-3, SCF, IL-6, and IL-11 in treating thrombocytopenia.

Suppression of normal hematopoiesis is a frequent complication of cancer or its treatment. The basis for dose-intensified cancer therapy in the 1990s was the discovery that hematopoietic growth factors and peripheral blood progenitor cell infusions can ameliorate some of its associated hematologic toxicities. Both granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor accelerate neutrophil recovery after chemotherapy and can mobilize peripheral blood progenitor cells for use in autologous or allogeneic transplantation. Unfortunately, the duration and severity of chemotherapy-induced thrombocytopenia is unaffected by the use of these myeloid growth factors. During the last 5 years, the activities of a variety of potential platelet or megakaryocyte-stimulating factors have been determined in clinical trials. The results of these studies are described.

正常造血功能受抑制是癌症或其治疗的常见并发症。20世纪90年代强化剂量癌症治疗的基础是发现造血生长因子和外周血祖细胞输注可改善一些相关的血液学毒性。粒细胞集落刺激因子和粒细胞 - 巨噬细胞集落刺激因子均可加速化疗后的中性粒细胞恢复，并可动员外周血祖细胞用于自体或异体移植。不幸的是，使用这些髓系生长因子对化疗诱导的血小板减少症的持续时间和严重程度没有影响。在过去5年中，多种潜在的血小板或巨核细胞刺激因子的活性已在临床试验中得到确定。本文描述了这些研究的结果。